NCT07026916View on ClinicalTrials.gov

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

83

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

August 1, 2028

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

GFH375

GFH375 will be administered at the 600mg QD, orally, until disease progression or intolerable toxicity.

All Listed Sponsors

lead

Genfleet Therapeutics (Shanghai) Inc.

INDUSTRY